Patent: 10,501,773
✉ Email this page to a colleague
Summary for Patent: 10,501,773
| Title: | Detection and classification of an anticoagulant using a clotting assay |
| Abstract: | In some embodiments, the invention provides methods for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control clotting measurement; and subjecting a sample of a blood component from a patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient clotting measurement, wherein the patient clotting measurement sample greater than the control clotting measurement indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient. In some embodiments, the invention includes methods for classifying an anticoagulant as an anti-Factor Xa or a direct thrombin inhibitor anticoagulant using a clotting assay in the presence of an ecarin reagent. |
| Inventor(s): | Zaman; Fowzia S. (Aurora, IL), Doubleday; Marc (Cary, IL) |
| Assignee: | Haemonetics Corporation (Braintree, MA) |
| Application Number: | 14/813,939 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,501,773
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | PRAXBIND | idarucizumab | Injection | 761025 | 10/16/2015 | ⤷ Try a Trial | 2034-07-31 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
